The Fort Worth Press - Bayer shares hit 20-yr low as problems pile up

USD -
AED 3.673006
AFN 67.000311
ALL 92.449862
AMD 387.650577
ANG 1.803609
AOA 912.000072
ARS 998.1981
AUD 1.540618
AWG 1.8
AZN 1.706465
BAM 1.839835
BBD 2.020546
BDT 119.582702
BGN 1.851502
BHD 0.376887
BIF 2898
BMD 1
BND 1.337466
BOB 6.915139
BRL 5.806962
BSD 1.000762
BTN 84.395861
BWP 13.578807
BYN 3.274884
BYR 19600
BZD 2.01714
CAD 1.39948
CDF 2865.000212
CHF 0.885795
CLF 0.035513
CLP 979.90972
CNY 7.2244
CNH 7.244355
COP 4479
CRC 511.011392
CUC 1
CUP 26.5
CVE 104.849946
CZK 23.9373
DJF 177.719992
DKK 7.06055
DOP 60.375024
DZD 133.998993
EGP 49.3251
ERN 15
ETB 122.049964
EUR 0.94655
FJD 2.27125
FKP 0.786951
GBP 0.78699
GEL 2.730338
GGP 0.786951
GHS 16.093319
GIP 0.786951
GMD 71.000122
GNF 8629.999871
GTQ 7.732613
GYD 209.3638
HKD 7.781365
HNL 25.060257
HRK 7.133507
HTG 131.582908
HUF 386.059763
IDR 15845.9
ILS 3.754225
IMP 0.786951
INR 84.42365
IQD 1310.5
IRR 42092.500584
ISK 139.430268
JEP 0.786951
JMD 158.431955
JOD 0.7091
JPY 155.550045
KES 129.495865
KGS 86.200902
KHR 4049.999849
KMF 466.350132
KPW 899.999851
KRW 1402.789736
KWD 0.30764
KYD 0.833937
KZT 493.231612
LAK 21944.999787
LBP 89550.000237
LKR 292.48469
LRD 183.999896
LSL 18.249631
LTL 2.95274
LVL 0.60489
LYD 4.869392
MAD 9.95797
MDL 18.032417
MGA 4655.000074
MKD 58.249992
MMK 3247.960992
MNT 3397.999858
MOP 8.017648
MRU 39.875002
MUR 46.889881
MVR 15.450612
MWK 1735.999923
MXN 20.534202
MYR 4.459733
MZN 63.899729
NAD 18.250197
NGN 1677.460255
NIO 36.78002
NOK 11.139895
NPR 135.035137
NZD 1.70113
OMR 0.384979
PAB 1.000724
PEN 3.80195
PGK 3.93475
PHP 58.837965
PKR 278.049733
PLN 4.10935
PYG 7810.118723
QAR 3.64055
RON 4.7105
RSD 110.736994
RUB 98.498646
RWF 1365
SAR 3.75755
SBD 8.383555
SCR 13.638838
SDG 601.502988
SEK 10.984375
SGD 1.343089
SHP 0.786951
SLE 22.814981
SLL 20969.507172
SOS 571.500104
SRD 35.279997
STD 20697.981008
SVC 8.756103
SYP 2512.530016
SZL 18.249869
THB 34.941496
TJS 10.662352
TMT 3.51
TND 3.147501
TOP 2.3421
TRY 34.35113
TTD 6.800373
TWD 32.450501
TZS 2659.999506
UAH 41.343769
UGX 3672.521001
UYU 42.190719
UZS 12825.000122
VES 44.996698
VND 25345
VUV 118.721975
WST 2.812855
XAF 617.092513
XAG 0.033008
XAU 0.000389
XCD 2.70255
XDR 0.753908
XOF 616.50203
XPF 113.349685
YER 249.80406
ZAR 18.240398
ZMK 9001.201813
ZMW 27.374927
ZWL 321.999592
  • CMSC

    0.0700

    24.61

    +0.28%

  • CMSD

    -0.0200

    24.73

    -0.08%

  • SCS

    -0.3000

    13.37

    -2.24%

  • NGG

    -0.7800

    62.12

    -1.26%

  • BCC

    1.4200

    142.55

    +1%

  • RBGPF

    -0.8500

    59.34

    -1.43%

  • AZN

    0.1000

    65.29

    +0.15%

  • GSK

    -0.4100

    35.11

    -1.17%

  • JRI

    0.0200

    13.24

    +0.15%

  • RIO

    -0.5800

    60.62

    -0.96%

  • BP

    0.4100

    28.57

    +1.44%

  • BTI

    0.1800

    35.42

    +0.51%

  • BCE

    -0.4800

    27.21

    -1.76%

  • RYCEF

    -0.0500

    7.11

    -0.7%

  • RELX

    -0.4700

    46.12

    -1.02%

  • VOD

    0.2800

    8.75

    +3.2%

Bayer shares hit 20-yr low as problems pile up
Bayer shares hit 20-yr low as problems pile up / Photo: © AFP

Bayer shares hit 20-yr low as problems pile up

Bayer's shares plunged to a 20-year low Tuesday after the German chemicals giant cut its earnings outlook and posted a worse-than-expected loss on woes related to its troubled agrochemicals division.

Text size:

The group vowed to press ahead with its cost-cutting efforts after reporting a loss of 4.18 billion euros ($4.45 billion) in the three months to the end of September, much worse than analysts' forecasts.

It was weighed down by bad news from its agrochemicals division, including a heavy drop in sales of its glyphosate-based weedkillers, at the centre of long-running legal fights in the United States over claims they cause cancer.

Earnings at the agricultural unit were also hit by a hefty writedown on assets.

Bayer, which also makes pharmaceuticals and consumer health products, saw its shares plunge more than 11 percent on the Frankfurt Stock Exchange after reporting its second quarterly loss in a row.

It is a fresh headache for CEO Bill Anderson, who was hired last year to steer the troubled group in a new direction, and has launched a major restructuring drive while resisting calls from activist investors for a break-up of the group.

They also reflect a bleak picture for Germany's traditional manufacturers generally, who are struggling with challenges ranging from high costs to weak demand, as Europe's top economy heads for a second straight year of contraction.

The problems for Bayer, the maker of Aspirin, looked set to continue in 2025 with chief financial officer Wolfgang Nickl warning of a "muted outlook" next year, "with likely declining earnings".

"We plan to accelerate our cost and efficiency measures," he said.

- 'No quick fix' -

After Tuesday's results, the Leverkusen-based group lowered its 2024 outlook for EBITDA -- or operating earnings, a key measure of profitability -- to between 10.4 billion and 10.7 billion euros from a previous forecast of between 10.7 billion and 11.3 billion euros.

It also cut the outlook for profit margins in the agrochemicals division.

Anderson is aiming to make savings of two billion euros a year from 2026, in particular by reducing management positions.

The group has already cut some 5,500 jobs since the start of the year, including 3,200 in the first half, according to the CEO.

It is also hoping for progress in resolving the massive litigation issues linked to the Roundup weedkiller, a problem it inherited in the 2018 takeover of US firm Monsanto.

The group has faced a wave of lawsuits in the United States over claims Roundup, which contains the active ingredient glyphosate, causes cancer. Bayer denies the claim but has spent billions of euros on legal costs.

It hopes the US Supreme Court will take up the cases related to Roundup in order to clarify the legal situation.

Bayer is considering which case to bring to the court and, if it does, would expect a decision in the 2025-26 term, said Anderson.

But he cautioned: "This is a long road, with no quick fix."

Sales overall edged up slightly in the quarter to 9.97 billion euros.

Away from the agrochemicals unit, the picture was brighter, with higher sales in the pharmaceuticals division due to strong sales of some blockbuster drugs.

The consumer health unit also reported higher earnings and sales.

L.Holland--TFWP